Soltox Botulinum Toxin Type A Brand package
CELSET
On Oct 28, 2026, South Korean medical aesthetics biotechnology company CELSET INC announced the launch of its botulinum toxin type A brand, SOLTOX, introducing another Korean botulinum toxin type A option for international medical aesthetics markets.
According to CELSET's Oct. 28, 2026, announcement, Soltox has three defining product characteristics: a 900-kDa toxin complex, a freeze-dried formulation and a purification process the company describes as advanced. It is offered in 100-unit and 200-unit formulations
Related: Achieving Longer Lasting Botulinum Toxin Injections
CELSET says the company’s focus on these attributes reflects a manufacturing approach that emphasizes controlled processing, product characterization, and pharmaceutical quality.
The company views these attributes as the technical foundation and defining characteristics of SOLTOX, as South Korea already has numerous botulinum toxin manufacturers.
Established competitors include Hugel and its Botulax/Letybo products, and Daewoong Pharmaceutical and its Nabota/Jeuveau products. Letybo and Jeuveau have already secured U.S. approvals.
As Korean biotechnology and medical aesthetics manufacturing grows, CELSET hopes SOLTOX draws attention to formulation identity and process controls without equating manufacturing characteristics with unverified differences in patient outcomes.
